<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01198405</url>
  </required_header>
  <id_info>
    <org_study_id>SYSU-5010-2008</org_study_id>
    <nct_id>NCT01198405</nct_id>
  </id_info>
  <brief_title>Study of Enahnced External Counterpulsation to Treat Coronary Heart Disease</brief_title>
  <acronym>PROBE-EECP</acronym>
  <official_title>A Prospective,Randomized,Open-labeled,and Blind Endpoint Study of Enhanced External Counterpulsation for Patients With Coronary Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the mid- and long-term effect of Enhanced External Counterpulsation combined
      with guideline-driven standard treatment on patients documented with and/or at high risk of
      coronary artery disease.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2008</start_date>
  <completion_date type="Anticipated">September 2013</completion_date>
  <primary_completion_date type="Anticipated">September 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>composite endpoint of rate of all-cause mortality, revascularization, rehospitalization and acute myocardial infarction</measure>
    <time_frame>up to 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>vascular endothelial function</measure>
    <time_frame>up to 5 years</time_frame>
    <description>measurment of flexibility of peripheral artery and flow-mediated dilatation (FMD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiac structure and exercise tolerance</measure>
    <time_frame>up to 5 years</time_frame>
    <description>cardiac chamber diameter, left ventricular wall thickness, ejection fraction, and etc., as deternmined by echocardiographic examination; exercise tolerance, as determined by Treadmill's Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>new-onset diabetes</measure>
    <time_frame>up to 5 years</time_frame>
    <description>fasting, postprandial and random plasma glucose levels; glycosylated hemoglobin A1c (GHbA1c)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>atherosclerosis</measure>
    <time_frame>up to 5 years</time_frame>
    <description>peripheral artery: plaque of common carotid artery, carotid intima-media Thickness, systolic and diastolic blood pressure (SBP &amp; DBP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24-hour urinary protein</measure>
    <time_frame>up to 5 years</time_frame>
    <description>24-hour urinary protein/albumin by urinalysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>all-cause mortality</measure>
    <time_frame>up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>revascularization rate</measure>
    <time_frame>up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rehospitalization rate</measure>
    <time_frame>up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of acute myocardial infarction</measure>
    <time_frame>up to 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1050</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Enhanced External Counterpulsation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment of Enhanced External Counterpulsation (EECP) with a prespecified protocol on top of guideline-driven standard medical therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Guideline-driven standard medical therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Enhanced external counterpulsation</intervention_name>
    <description>Treatment of enhanced external counterpulsation (EECP) with a prespecified protocol on top of a guideline-driven standard medical therapy. EECP Protocol is defined as a standard session of a total of 36 hours of EECP treatment, given one hour per day, six days per week. The same session is thereafter repeated at least once every year.</description>
    <arm_group_label>Enhanced External Counterpulsation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Guideline-driven standard medical therapy</intervention_name>
    <description>Standard management, both pharmacological and non-pharmacological, given according to current practice guidelines at the discretion of clinicians</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  at least one coronary lesion of more than 50% stenosis shown by angiography

          -  history of acute myocardial infarction(at least one month before)

          -  history of prior revascularization (Percutaneous Coronary Intervention or Coronary
             Artery Bypass Grafting)

          -  typical angina episodes with evidence of myocardial ischemia

          -  Signed informed consent

        Exclusion Criteria:

          -  Obvious aortic insufficiency, aortic aneurysm, aortic dissection

          -  Coronary fistula or severe coronary aneurysm

          -  Symptomatic Congestive heart failure

          -  Valvular heart disease, congenital heart diseases, cardiomyopathies

          -  Cerebral hemorrhage within six months, bleeding disorders or identified bleeding
             tendency;

          -  Lower limb infection, phlebitis, varicosity, deep venous thrombosis;

          -  Progressive malignancies or diseases with poor prognosis;

          -  uncontrolled hypertension, defined as SBP≥180mmHg or DBP≥110mmHg
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhi-min Du, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The 1st Affiliated Hospital of Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gui-fu Wu, M.D. &amp; Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>The 1st Affiliated Hospital of Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yan Zhang, M.D.</last_name>
    <phone>+86-137-1123-4160</phone>
    <email>zhangyan1233456@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Qiang Xie, M.D.</last_name>
    <phone>+86-138-0273-9667</phone>
    <email>qiangxie2010@sohu.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The 1st Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gui-fu Wu, M.D. &amp; Ph.D.</last_name>
      <phone>+86-135-7001-0112</phone>
      <email>eecpchina@yahoo.com.cn</email>
    </contact>
    <contact_backup>
      <last_name>Da-ya Yang, M.D.</last_name>
      <phone>+86-135-7056-7490</phone>
      <email>y2kchocolate@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Zhi-min Du, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The 2nd Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jing-feng Wang, M.D.</last_name>
      <phone>+86-136-0289-0860</phone>
    </contact>
    <contact_backup>
      <last_name>Ru-qiong Nie, M.D.</last_name>
      <phone>+86-136-0047-9016</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The 3rd Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lin Chen, M.D.</last_name>
      <phone>+86-138-0251-8615</phone>
    </contact>
    <contact_backup>
      <last_name>Xiao-xian Qian, M.D.</last_name>
      <phone>+86-137-1926-1500</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The 5th Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Zhuhai</city>
        <state>Guangdong</state>
        <zip>519000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jian Peng, M.D.</last_name>
      <phone>+86-136-0036-1608</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Loh PH, Cleland JG, Louis AA, Kennard ED, Cook JF, Caplin JL, Barsness GW, Lawson WE, Soran OZ, Michaels AD. Enhanced external counterpulsation in the treatment of chronic refractory angina: a long-term follow-up outcome from the International Enhanced External Counterpulsation Patient Registry. Clin Cardiol. 2008 Apr;31(4):159-64. doi: 10.1002/clc.20117.</citation>
    <PMID>18404725</PMID>
  </reference>
  <reference>
    <citation>Kitsou V, Xanthos T, Roberts R, Karlis GM, Padadimitriou L. Enhanced external counterpulsation: mechanisms of action and clinical applications. Acta Cardiol. 2010 Apr;65(2):239-47. Review.</citation>
    <PMID>20458834</PMID>
  </reference>
  <reference>
    <citation>Manchanda A, Soran O. Enhanced external counterpulsation and future directions: step beyond medical management for patients with angina and heart failure. J Am Coll Cardiol. 2007 Oct 16;50(16):1523-31. Epub 2007 Oct 1. Review. Erratum in: J Am Coll Cardiol. 2007 Dec 18;50(25):2441.</citation>
    <PMID>17936150</PMID>
  </reference>
  <reference>
    <citation>Michaels AD, McCullough PA, Soran OZ, Lawson WE, Barsness GW, Henry TD, Linnemeier G, Ochoa A, Kelsey SF, Kennard ED. Primer: practical approach to the selection of patients for and application of EECP. Nat Clin Pract Cardiovasc Med. 2006 Nov;3(11):623-32. Review.</citation>
    <PMID>17063167</PMID>
  </reference>
  <reference>
    <citation>Cohn PF. Enhanced external counterpulsation for the treatment of angina pectoris. Prog Cardiovasc Dis. 2006 Sep-Oct;49(2):88-97. Review.</citation>
    <PMID>17046434</PMID>
  </reference>
  <reference>
    <citation>O'Rourke MF, Hashimoto J. Enhanced external counterpulsation why the benefit? J Am Coll Cardiol. 2006 Sep 19;48(6):1215-6. Epub 2006 Aug 28. Review.</citation>
    <PMID>16979008</PMID>
  </reference>
  <reference>
    <citation>Michaels AD, Raisinghani A, Soran O, de Lame PA, Lemaire ML, Kligfield P, Watson DD, Conti CR, Beller G. The effects of enhanced external counterpulsation on myocardial perfusion in patients with stable angina: a multicenter radionuclide study. Am Heart J. 2005 Nov;150(5):1066-73.</citation>
    <PMID>16291000</PMID>
  </reference>
  <reference>
    <citation>Arora RR, Chou TM, Jain D, Fleishman B, Crawford L, McKiernan T, Nesto R, Ferrans CE, Keller S. Effects of enhanced external counterpulsation on Health-Related Quality of Life continue 12 months after treatment: a substudy of the Multicenter Study of Enhanced External Counterpulsation. J Investig Med. 2002 Jan;50(1):25-32. doi: 10.2310/6650.2002.33514.</citation>
    <PMID>11813825</PMID>
  </reference>
  <reference>
    <citation>Arora RR, Chou TM, Jain D, Fleishman B, Crawford L, McKiernan T, Nesto RW. The multicenter study of enhanced external counterpulsation (MUST-EECP): effect of EECP on exercise-induced myocardial ischemia and anginal episodes. J Am Coll Cardiol. 1999 Jun;33(7):1833-40.</citation>
    <PMID>10362181</PMID>
  </reference>
  <verification_date>January 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2010</study_first_submitted>
  <study_first_submitted_qc>September 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2010</study_first_posted>
  <last_update_submitted>September 9, 2010</last_update_submitted>
  <last_update_submitted_qc>September 9, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2010</last_update_posted>
  <responsible_party>
    <name_title>Gui-Fu Wu</name_title>
    <organization>The First Affiliated Hospital of Sun Yat-Sen University</organization>
  </responsible_party>
  <keyword>coronary artery disease</keyword>
  <keyword>enhanced external counterpulsation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

